Knight Therapeutics (GUD) Competitors C$5.19 +0.03 (+0.58%) (As of 12/20/2024 05:17 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider Trades GUD vs. TLRY, CRON, THCX, WEED, CPH, ACB, FIRE, EPI, OGI, and ICCShould you be buying Knight Therapeutics stock or one of its competitors? The main competitors of Knight Therapeutics include Tilray Brands (TLRY), Cronos Group (CRON), Hydropothecary (THCX), Canopy Growth (WEED), Cipher Pharmaceuticals (CPH), Aurora Cannabis (ACB), Supreme Cannabis (FIRE), ESSA Pharma (EPI), Organigram (OGI), and ICC Labs (ICC). These companies are all part of the "drug manufacturers - specialty & generic" industry. Knight Therapeutics vs. Tilray Brands Cronos Group Hydropothecary Canopy Growth Cipher Pharmaceuticals Aurora Cannabis Supreme Cannabis ESSA Pharma Organigram ICC Labs Tilray Brands (TSE:TLRY) and Knight Therapeutics (TSE:GUD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, community ranking, institutional ownership and dividends. Which has better earnings & valuation, TLRY or GUD? Knight Therapeutics has lower revenue, but higher earnings than Tilray Brands. Knight Therapeutics is trading at a lower price-to-earnings ratio than Tilray Brands, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTilray BrandsC$788.94M1.98-C$244.98M-C$0.45-3.96Knight TherapeuticsC$337.87M1.55-C$21.23M-C$0.20-25.95 Do analysts prefer TLRY or GUD? Tilray Brands presently has a consensus target price of C$2.95, suggesting a potential upside of 65.73%. Knight Therapeutics has a consensus target price of C$7.08, suggesting a potential upside of 36.48%. Given Tilray Brands' higher possible upside, equities research analysts clearly believe Tilray Brands is more favorable than Knight Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tilray Brands 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Knight Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Which has more risk and volatility, TLRY or GUD? Tilray Brands has a beta of 2.19, indicating that its share price is 119% more volatile than the S&P 500. Comparatively, Knight Therapeutics has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500. Does the MarketBeat Community believe in TLRY or GUD? Knight Therapeutics received 112 more outperform votes than Tilray Brands when rated by MarketBeat users. Likewise, 73.68% of users gave Knight Therapeutics an outperform vote while only 0.00% of users gave Tilray Brands an outperform vote. CompanyUnderperformOutperformTilray BrandsOutperform VotesNo VotesUnderperform Votes7100.00% Knight TherapeuticsOutperform Votes11273.68% Underperform Votes4026.32% Do insiders and institutionals believe in TLRY or GUD? 11.2% of Tilray Brands shares are owned by institutional investors. Comparatively, 12.6% of Knight Therapeutics shares are owned by institutional investors. 0.7% of Tilray Brands shares are owned by insiders. Comparatively, 45.6% of Knight Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is TLRY or GUD more profitable? Knight Therapeutics has a net margin of -6.28% compared to Tilray Brands' net margin of -31.05%. Knight Therapeutics' return on equity of -2.70% beat Tilray Brands' return on equity.Company Net Margins Return on Equity Return on Assets Tilray Brands-31.05% -6.57% -1.41% Knight Therapeutics -6.28%-2.70%0.51% Does the media refer more to TLRY or GUD? In the previous week, Tilray Brands had 2 more articles in the media than Knight Therapeutics. MarketBeat recorded 2 mentions for Tilray Brands and 0 mentions for Knight Therapeutics. Tilray Brands' average media sentiment score of 0.81 beat Knight Therapeutics' score of 0.00 indicating that Tilray Brands is being referred to more favorably in the media. Company Overall Sentiment Tilray Brands Positive Knight Therapeutics Neutral SummaryKnight Therapeutics beats Tilray Brands on 12 of the 19 factors compared between the two stocks. Ad Behind the MarketsWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.Take these 4 steps today to protect your retirement NOW Get Knight Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GUD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GUD vs. The Competition Export to ExcelMetricKnight TherapeuticsDrug Manufacturers IndustryMedical SectorTSE ExchangeMarket CapC$525.28MC$1.17BC$5.14BC$6.07BDividend YieldN/A3.04%5.09%5.42%P/E Ratio-25.95131.2390.0526.16Price / Sales1.551,981.001,117.141,332.85Price / Cash3.8510.2543.0482.30Price / Book0.693.084.783.07Net Income-C$21.23MC$152.21MC$120.31MC$295.24M7 Day Performance-0.19%-0.48%-1.92%-2.48%1 Month Performance-2.08%-1.33%11.51%-0.78%1 Year Performance1.37%99.54%30.61%34.67% Knight Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GUDKnight TherapeuticsN/AC$5.19+0.6%C$7.08+36.5%+0.0%C$525.28MC$337.87M-25.95725TLRYTilray Brands0.638 of 5 starsC$1.70-0.6%C$2.95+73.5%-33.6%C$1.49BC$788.94M-3.802,650CRONCronos Group1.0954 of 5 starsC$2.76+1.1%C$3.18+15.2%+12.5%C$1.06BC$101.78M-13.19450News CoverageTHCXHydropothecaryN/AC$5.30+6.6%N/A+0.0%C$949.11MN/A0.00N/AHigh Trading VolumeWEEDCanopy Growth1.2354 of 5 starsC$4.37-1.1%C$7.12+62.9%-36.9%C$370.84MC$287.10M-0.562,700Analyst DowngradeCPHCipher Pharmaceuticals0.42 of 5 starsC$14.16-0.6%C$12.50-11.7%+157.7%C$362.35MC$22.16M11.395ACBAurora Cannabis0.2839 of 5 starsC$6.14-0.2%C$6.35+3.4%+876.2%C$335.61MC$278.98M-9.761,073Analyst ForecastAnalyst RevisionNews CoverageFIRESupreme CannabisN/AC$0.34+3.0%N/AN/AC$259.40MC$53.29M-10.81400News CoverageEPIESSA PharmaN/AC$8.20+7.2%N/A+0.0%C$237.87MN/A-8.2725OGIOrganigram3.1639 of 5 starsC$2.19+4.3%C$3.86+76.4%+36.2%C$237.77MC$149.21M-0.84987Analyst ForecastAnalyst RevisionNews CoverageICCICC LabsN/AC$1.62-5.8%N/A+0.0%C$223.64MC$533,684.0095.29N/AGap Up Related Companies and Tools Related Companies TLRY Alternatives CRON Alternatives THCX Alternatives WEED Alternatives CPH Alternatives ACB Alternatives FIRE Alternatives EPI Alternatives OGI Alternatives ICC Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (TSE:GUD) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Knight Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Knight Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GUD Stock Alerts